A Systematic Literature Review and Network Meta Analysis of Insulin Icodec With Other Basal Insulins in Insulin Naïve Patients With Type 2 Diabetes
Author(s)
Bøg M1, LeReun C2, Gupta P3, Chubb B4, Jensen MS5, Nair S6
1Novo Nordisk A/S, Søborg, 85, Denmark, 2Clarivate Analytics Ltd, London, UK, 3Clarivate Analytics Ltd, Bangalore, India, 4Novo Nordisk A/S, Gatwick, UK, 5Novo Nordisk A/S, Søborg, Denmark, 6Clarivate Analytics Ltd, Mumbai, MH, India
OBJECTIVES: A network meta-analysis (NMA) was conducted to compare the efficacy and safety of insulin icodec with other basal insulins for the management of insulin naïve patients with type 2 diabetes (T2D), based on studies identified through a systematic literature review (SLR).
METHODS: A SLR was conducted in October 2023 to identify randomised controlled trials (RCTs) examining treatments of interest (insulin icodec, insulin glargine [IGlar U100, IGlar U300], insulin detemir, and insulin degludec) in this population. Where possible, data at 52 ± 4 weeks were extracted for outcomes selected for the NMA including change from baseline in glycated haemoglobin (HbA1c), and proportion of patients with clinically significant hypoglycaemic events. However, in some cases, comparisons were only possible at 26 ± 4 weeks. Fixed- and random-effects NMA were fitted in a Bayesian setting.
RESULTS: Treatment with insulin icodec was associated with significantly greater HbA1c reductions at 52 ± 4 weeks compared with IGlar U100, insulin detemir, and insulin degludec U100, with treatment differences of −0.19% (95% credible interval [Crl]; −0.35, −0.03), −0.24% (95% Crl; −0.47, −0.01), and −0.28% (95% Crl; −0.49, −0.07), respectively. Treatment with insulin icodec was associated with numerically greater HbA1c reductions at 26 ± 4 weeks compared with IGlar U300, with a treatment difference of −0.19% (95% Crl; −0.49, 0.1). Treatment with insulin icodec was associated with numerically lower odds of clinically significant hypoglycaemia at 52 ± 4 weeks compared with IGlar U100 (odds ratio, 0.91 [95% Crl; 0.60, 1.38]) and insulin degludec U100 (odds ratio, 0.91 [95% Crl; 0.55, 1.50]).
CONCLUSIONS: Insulin naïve patients with T2D had significantly greater HbA1c reductions at 52 ± 4 weeks with insulin icodec compared with IGlar U100, insulin detemir and insulin degludec, with no increased risk of hypoglycaemic events.
Conference/Value in Health Info
Value in Health, Volume 27, Issue 12, S2 (December 2024)
Code
CO189
Topic
Clinical Outcomes, Study Approaches
Topic Subcategory
Comparative Effectiveness or Efficacy, Literature Review & Synthesis, Meta-Analysis & Indirect Comparisons
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity), No Additional Disease & Conditions/Specialized Treatment Areas